输血诱导的HLA致敏在等待名单患者和肾移植受者中的研究进展
本文综述了输血诱导的HLA致敏在等待名单患者和肾移植受者中的现有证据,指出针对HLA抗体的治疗缺乏长期有效性,预防致敏应优先;尽管贫血管理进步,输血需求仍存在,且移植后输血常见,但全球多数注册系统未常规收集输血数据,限制了证据;强调肾移植领域亟需患者血液管理指南。
要点
- 预防HLA致敏应优先于等待名单和移植受者。
- 新贫血治疗未消除输血需求,移植后输血常见。
- 多数注册系统缺乏输血数据,需患者血液管理指南。
核心结论
- 预防HLA致敏应作为等待名单候选者和移植受者的优先事项。
- 肾移植领域亟需患者血液管理指南以指导输血实践。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 针对HLA抗体的当前治疗缺乏长期有效性。
- 新型贫血治疗研究显示输血需求仍将存在。
- 肾移植后输血常见,尤其围手术期。
- 全球多数肾脏和移植注册系统未常规收集输血发生率、指征和结局数据。
临床怎么用
- 临床应重视预防HLA致敏,减少不必要的输血。
- 需建立肾移植患者血液管理指南以规范输血实践。
局限性
- 输血相关数据未被多数注册系统常规收集,限制证据强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human leukocyte antigen (HLA) sensitization remains an impediment to successful solid organ transplantation, whether it be chances of receiving a transplant offer or subsequent transplant longevity. Current treatments targeting HLA antibodies lack long-term effectiveness; therefore, preventing HLA sensitization should remain a priority in all potential wait-list candidates and transplant recipients. Recent advances in the management of anemia in patients with chronic kidney disease may reduce the need for red cell transfusions. However, data from several anemia intervention studies of novel therapeutic agents have shown that a need for transfusion will remain. It has also been increasingly recognized that blood transfusions following kidney transplantation, especially in the peri-operative period, are common. Routine data on transfusion incidence, indications, and outcomes are not captured by most kidney and transplant registries across the globe. This restricts the evidence to inform both clinicians and patients on the clinical effects of transfusion, which have been considered both an allogeneic stimulus and to be immunomodulatory.This review aims to provide an update on what is currently known about transfusion-induced HLA sensitization in wait-list candidates and transplant recipients, summarizes where evidence is lacking, and demonstrates the distinct need for patient blood management guidelines in the field of kidney transplantation.
引用
- Willicombe M, Roberts DJ. Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients. Kidney Int. 2024. PMID: 39181398. doi:10.1016/j.kint.2024.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。